Abstract
The calcium (Ca2+)-sensitizer, levosimendan, is recommended by the European Heart Association and the European Society of Intensive Care Medicine for the treatment of low output heart failure, when standard treatment is insufficient [1]. Despite encouraging results from experimental and randomized clinical studies, a recent large randomized, double-blind, multicenter trial in patients with acute decompensated heart failure (Survival Of Patients With Acute Heart Failure In Need Of Intravenous Inotropic Support, SURVIVE study), did not reveal any significant reduction in 31- or 180-day mortality with levosimendan compared to dobutamine [2]. The elementary question that needs to be addressed and was recently elegantly worded by Dr. Butler and colleagues, is whether to abandon or not to abandon levosimendan? [3].
| Original language | English (US) |
|---|---|
| Title of host publication | Yearbook of Intensive Care and Emergency Medicine 2009 |
| Publisher | Springer New York |
| Pages | 498-510 |
| Number of pages | 13 |
| ISBN (Print) | 9780387922775 |
| DOIs | |
| State | Published - 2007 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Role of the calcium sensitizer, levosimendan, in perioperative intensive care medicine. / Rehberg, S.; Enkhbaatar, Perenlei; Traber, D. L.
Yearbook of Intensive Care and Emergency Medicine 2009. Springer New York, 2007. p. 498-510.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - Role of the calcium sensitizer, levosimendan, in perioperative intensive care medicine
AU - Rehberg, S.
AU - Enkhbaatar, Perenlei
AU - Traber, D. L.
PY - 2007
Y1 - 2007
N2 - The calcium (Ca2+)-sensitizer, levosimendan, is recommended by the European Heart Association and the European Society of Intensive Care Medicine for the treatment of low output heart failure, when standard treatment is insufficient [1]. Despite encouraging results from experimental and randomized clinical studies, a recent large randomized, double-blind, multicenter trial in patients with acute decompensated heart failure (Survival Of Patients With Acute Heart Failure In Need Of Intravenous Inotropic Support, SURVIVE study), did not reveal any significant reduction in 31- or 180-day mortality with levosimendan compared to dobutamine [2]. The elementary question that needs to be addressed and was recently elegantly worded by Dr. Butler and colleagues, is whether to abandon or not to abandon levosimendan? [3].
AB - The calcium (Ca2+)-sensitizer, levosimendan, is recommended by the European Heart Association and the European Society of Intensive Care Medicine for the treatment of low output heart failure, when standard treatment is insufficient [1]. Despite encouraging results from experimental and randomized clinical studies, a recent large randomized, double-blind, multicenter trial in patients with acute decompensated heart failure (Survival Of Patients With Acute Heart Failure In Need Of Intravenous Inotropic Support, SURVIVE study), did not reveal any significant reduction in 31- or 180-day mortality with levosimendan compared to dobutamine [2]. The elementary question that needs to be addressed and was recently elegantly worded by Dr. Butler and colleagues, is whether to abandon or not to abandon levosimendan? [3].
UR - http://www.scopus.com/inward/record.url?scp=77957246033&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77957246033&partnerID=8YFLogxK
U2 - 10.1007/978-0-387-92278-2_47
DO - 10.1007/978-0-387-92278-2_47
M3 - Chapter
SN - 9780387922775
SP - 498
EP - 510
BT - Yearbook of Intensive Care and Emergency Medicine 2009
PB - Springer New York
ER -